

**Anti-FLT3 / CD135 Reference Antibody (IMC-EB10)**  
**Recombinant Antibody**  
**Catalog # APR10509**

**Specification**

---

**Anti-FLT3 / CD135 Reference Antibody (IMC-EB10) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P36888</a>
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

**Anti-FLT3 / CD135 Reference Antibody (IMC-EB10) - Additional Information**

**Target/Specificity**  
FLT3 / CD135

**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

**Anti-FLT3 / CD135 Reference Antibody (IMC-EB10) - Protein Information**

**Name** FLT3

**Synonyms** CD135, FLK2, STK1

**Function**  
Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only

marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.

#### Cellular Location

Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen.

Note=Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation

#### Tissue Location


Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia

### Anti-FLT3 / CD135 Reference Antibody (IMC-EB10) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-FLT3 / CD135 Reference Antibody (IMC-EB10) - Images



Anti-FLT3 / CD135 Reference Antibody (IMC-EB10) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-FLT3 / CD135 Reference Antibody (IMC-EB10) is more than 95% ,determined by SEC-HPLC.